Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (101-110 of 301) with videos related to

Pageof 31
Sort By:
Risk Analysis : an Official Publication of the Society for Risk Analysis|July 13, 2006
What affects the quality of economic analysis for life-saving investments?Robert W Hahn, Katrina Kosec, Peter J Neumann, et al.
Health Affairs (Project Hope)|August 5, 2015
Private payers disagree with Medicare over medical device coverage about half the timeJames D Chambers, Matthew Chenoweth, Teja Thorat, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 10, 2022
A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional IssuesMeghan I Podolsky, Isabel Present, Peter J Neumann, et al.
Health Affairs (Project Hope)|October 6, 2010
A flexible approach to evidentiary standards for comparative effectiveness researchLouis P Garrison, Peter J Neumann, Paul Radensky, et al.
International Journal of Technology Assessment in Health Care|August 23, 2005
Diffusion of published cost-utility analyses in the field of health policy and practiceSeema S Sonnad, Dan Greenberg, Allison B Rosen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 15, 2006
Trends in the measurement of health utilities in published cost-utility analysesCarmen A Brauer, Allison B Rosen, Dan Greenberg, et al.
Health Affairs (Project Hope)|August 9, 2017
Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional ProcessJames D Chambers, Teja Thorat, Colby L Wilkinson, et al.
The American Journal of Managed Care|January 9, 2026
Communication of launch prices by drug companies, 2022-2024Brian Reid, Joshua T Cohen, Pei-Jung Lin, et al.
Journal of Medical Economics|February 22, 2011
Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDSMaki S Kamae, Isao Kamae, Joshua T Cohen, et al.
The American Journal of Managed Care|April 17, 2010
Low-value services in value-based insurance designPeter J Neumann, Hannah R Auerbach, Joshua T Cohen, et al.
Pageof 31

Showing results (101-110 of 301) with videos related to

Sort By:
Pageof 31
Risk Analysis : an Official Publication of the Society for Risk Analysis|July 13, 2006
What affects the quality of economic analysis for life-saving investments?Robert W Hahn, Katrina Kosec, Peter J Neumann, et al.
Health Affairs (Project Hope)|August 5, 2015
Private payers disagree with Medicare over medical device coverage about half the timeJames D Chambers, Matthew Chenoweth, Teja Thorat, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 10, 2022
A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional IssuesMeghan I Podolsky, Isabel Present, Peter J Neumann, et al.
Health Affairs (Project Hope)|October 6, 2010
A flexible approach to evidentiary standards for comparative effectiveness researchLouis P Garrison, Peter J Neumann, Paul Radensky, et al.
International Journal of Technology Assessment in Health Care|August 23, 2005
Diffusion of published cost-utility analyses in the field of health policy and practiceSeema S Sonnad, Dan Greenberg, Allison B Rosen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 15, 2006
Trends in the measurement of health utilities in published cost-utility analysesCarmen A Brauer, Allison B Rosen, Dan Greenberg, et al.
Health Affairs (Project Hope)|August 9, 2017
Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional ProcessJames D Chambers, Teja Thorat, Colby L Wilkinson, et al.
The American Journal of Managed Care|January 9, 2026
Communication of launch prices by drug companies, 2022-2024Brian Reid, Joshua T Cohen, Pei-Jung Lin, et al.
Journal of Medical Economics|February 22, 2011
Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDSMaki S Kamae, Isao Kamae, Joshua T Cohen, et al.
The American Journal of Managed Care|April 17, 2010
Low-value services in value-based insurance designPeter J Neumann, Hannah R Auerbach, Joshua T Cohen, et al.
Pageof 31